Eosinophilic Granulomatosis With Polyangiitis Egpa clinical trials

Explore recruiting eosinophilic granulomatosis with polyangiitis egpa clinical trials.

Recruiting eosinophilic granulomatosis with polyangiitis egpa studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Eosinophilic Granulomatosis With Polyangiitis Egpa trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

eGPA and local inflammation within the ENT area; Impact of Mepolizumab treatment on the nasal microbiome and local and systemic immune response in eosinophilic granulomatosis with polyangitis (eGPA)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in EGPA- RACE-MATE

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

Italy, France, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study).

Italy, France, Belgium, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

Belgium, Spain, Netherlands, Sweden, France, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

E-merge - Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Eosinophilic Granulomatosis With Polyangiitis Egpa trials by city

Eosinophilic Granulomatosis With Polyangiitis Egpa in Toronto Eosinophilic Granulomatosis With Polyangiitis Egpa in Vancouver Eosinophilic Granulomatosis With Polyangiitis Egpa in Montreal Eosinophilic Granulomatosis With Polyangiitis Egpa in Calgary Eosinophilic Granulomatosis With Polyangiitis Egpa in Edmonton Eosinophilic Granulomatosis With Polyangiitis Egpa in Ottawa Eosinophilic Granulomatosis With Polyangiitis Egpa in Winnipeg Eosinophilic Granulomatosis With Polyangiitis Egpa in Quebec City Eosinophilic Granulomatosis With Polyangiitis Egpa in Hamilton Eosinophilic Granulomatosis With Polyangiitis Egpa in Kitchener Eosinophilic Granulomatosis With Polyangiitis Egpa in London Eosinophilic Granulomatosis With Polyangiitis Egpa in Halifax Eosinophilic Granulomatosis With Polyangiitis Egpa in New York Eosinophilic Granulomatosis With Polyangiitis Egpa in Los Angeles Eosinophilic Granulomatosis With Polyangiitis Egpa in Chicago Eosinophilic Granulomatosis With Polyangiitis Egpa in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease